OTCMKTS:HKMPY Hikma Pharmaceuticals - HKMPY Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. $41.50 -0.05 (-0.12%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$41.50▼$41.5050-Day Range$40.75▼$43.7752-Week Range$25.12▼$56.77Volume497 shsAverage Volume1,613 shsMarket CapitalizationN/AP/E Ratio13.41Dividend Yield0.77%Price TargetN/A ProfileChartCompetitorsDividendHeadlinesShort Interest About Hikma Pharmaceuticals (OTCMKTS:HKMPY) StockHikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and is sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd., and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.Read More Receive HKMPY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address HKMPY Stock News HeadlinesMarch 19, 2023 | finance.yahoo.comHikma Pharmaceuticals Full Year 2022 Earnings: EPS Misses ExpectationsFebruary 7, 2023 | uk.investing.comHikma Pharmaceuticals PLC (HIK)April 1, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.January 31, 2023 | marketwatch.comHikma Pharmaceuticals rises Tuesday, outperforms marketJanuary 24, 2023 | marketwatch.comHikma Pharmaceuticals falls Tuesday, underperforms marketDecember 27, 2022 | msn.comJunshi inks licensing deal with Hikma for toripalimab; FDA filing still under reviewDecember 15, 2022 | marketwatch.comHikma Pharmaceuticals rises Thursday, outperforms marketOctober 9, 2022 | finance.yahoo.comHikma Pharmaceuticals PLC (HKMPY)April 1, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.September 28, 2022 | reuters.comHKMPY.PK - | Stock Price & Latest News | ReutersSeptember 25, 2022 | uk.finance.yahoo.comHikma Pharmaceuticals PLC (H5P.F)August 30, 2022 | finance.yahoo.comHikma launches RYALTRIS™ seasonal allergic rhinitis nasal spray in the USJuly 17, 2022 | benzinga.comHikma Pharmaceuticals (OTC:HKMPY), Analyst Ratings, Price Targets, PredictionsMay 14, 2022 | finance.yahoo.comInvestors in Hikma Pharmaceuticals (LON:HIK) have unfortunately lost 26% over the last yearApril 21, 2022 | finance.yahoo.comHikma completes acquisition of CustopharmApril 20, 2022 | seekingalpha.comHikma gets preliminary approval from FTC to acquire CustopharmApril 20, 2022 | finance.yahoo.comHikma confirms FTC preliminary approval for CustopharmApril 19, 2022 | finance.yahoo.comU.S. FTC approves Hikma deal for Custopharm with conditionsFebruary 27, 2022 | finance.yahoo.comAnalysts Have Made A Financial Statement On Hikma Pharmaceuticals PLC's (LON:HIK) Yearly ReportNovember 9, 2021 | finance.yahoo.comThose who invested in Hikma Pharmaceuticals (LON:HIK) five years ago are up 62%October 22, 2021 | finance.yahoo.comHikma donates 50,000 doses of injectable naloxone to help expand non-profit access to lifesaving treatment for reversing opioid overdosesSeptember 27, 2021 | finance.yahoo.comHikma Bolsters Injectable Portfolio With $375M Custopharm AcquisitionSeptember 27, 2021 | finance.yahoo.comHikma strengthens US Injectables business through acquisition of CustopharmJuly 7, 2021 | finance.yahoo.comIs Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 25% Discount?June 21, 2021 | finance.yahoo.comU.S. Supreme Court denies Amarin's bid to revive Vascepa drug patentsJune 21, 2021 | finance.yahoo.comUPDATE 1-U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patentsApril 21, 2021 | finance.yahoo.comHikma Pharmaceuticals PLC -- Moody's withdraws Hikma's ratings for business reasonsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive HKMPY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address HKMPY Company Calendar Ex-Dividend for 5/15 Dividend3/23/2023Today4/01/2023Dividend Payable5/15/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:HKMPY CUSIPN/A CIKN/A Webwww.hikma.com Phone442073992760FaxN/AEmployees8,700Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio13.41 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Key ExecutivesSaid Samih Taleb DarwazahExecutive Chairman & Chief Executive OfficerKhalid Walid Hosni NabilsiChief Financial OfficerMazen Samih Taleb DarwazahExecutive Vice Chairman & President-MENA RegionMajda LabadiExecutive VP-Organizational DevelopmentRiad MishlawiPresident-Injectables DivisionKey Competitors1933 IndustriesOTCMKTS:TGIFF4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFAcreageOTCMKTS:ACRHFView All Competitors HKMPY Stock - Frequently Asked Questions How have HKMPY shares performed in 2023? Hikma Pharmaceuticals' stock was trading at $36.95 at the beginning of 2023. Since then, HKMPY shares have increased by 12.3% and is now trading at $41.50. View the best growth stocks for 2023 here. Are investors shorting Hikma Pharmaceuticals? Hikma Pharmaceuticals saw a decrease in short interest in February. As of February 15th, there was short interest totaling 2,300 shares, a decrease of 14.8% from the January 31st total of 2,700 shares. Based on an average daily volume of 1,400 shares, the days-to-cover ratio is presently 1.6 days. View Hikma Pharmaceuticals' Short Interest. How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals? Hikma Pharmaceuticals declared a dividend on Friday, March 17th. Shareholders of record on Friday, March 24th will be paid a dividend of $0.72 per share on Monday, May 15th. This represents a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, March 23rd. This is a boost from the stock's previous dividend of $0.36. Read our dividend analysis for HKMPY. Is Hikma Pharmaceuticals a good dividend stock? Hikma Pharmaceuticals (OTCMKTS:HKMPY) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.65%. The dividend payout ratio is 10.34%. This payout ratio is at a healthy, sustainable level, below 75%. Read our dividend analysis for HKMPY. What is Hikma Pharmaceuticals' stock symbol? Hikma Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HKMPY." How do I buy shares of Hikma Pharmaceuticals? Shares of HKMPY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Hikma Pharmaceuticals' stock price today? One share of HKMPY stock can currently be purchased for approximately $41.50. How many employees does Hikma Pharmaceuticals have? The company employs 8,700 workers across the globe. How can I contact Hikma Pharmaceuticals? Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The official website for the company is www.hikma.com. The company can be reached via phone at 442073992760. This page (OTCMKTS:HKMPY) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.